Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Treasury Shares (2016 - 2025)

Regenxbio has reported Treasury Shares over the past 9 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Treasury Shares at $2.8 million for Q4 2025, up 39.57% from a year ago — trailing twelve months through Dec 2025 was $2.8 million (up 39.57% YoY), and the annual figure for FY2025 was $2.8 million, up 39.57%.
  • Treasury Shares for Q4 2025 was $2.8 million at Regenxbio, down from $2.9 million in the prior quarter.
  • Over the last five years, Treasury Shares for RGNX hit a ceiling of $3.0 million in Q2 2025 and a floor of $254000.0 in Q1 2021.
  • Median Treasury Shares over the past 5 years was $1.4 million (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Treasury Shares: surged 200.42% in 2023 and later grew 17.13% in 2024.
  • Regenxbio's Treasury Shares stood at $277000.0 in 2021, then skyrocketed by 121.3% to $613000.0 in 2022, then soared by 113.54% to $1.3 million in 2023, then soared by 56.0% to $2.0 million in 2024, then skyrocketed by 39.57% to $2.8 million in 2025.
  • The last three reported values for Treasury Shares were $2.8 million (Q4 2025), $2.9 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.